These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3392741)

  • 1. Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients.
    Davis LE; Alberts DS; Plezia PM; Roe DJ; Griswold DP
    J Natl Cancer Inst; 1988 Aug; 80(11):815-9. PubMed ID: 3392741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
    J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man.
    Scheithauer W; Clark GM; Salmon SE; Dorda W; Shoemaker RH; Von Hoff DD
    Cancer Treat Rep; 1986 Dec; 70(12):1379-82. PubMed ID: 3791251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal toxicology for early clinical trials with anticancer agents.
    Rozencweig M; Von Hoff DD; Staquet MJ; Schein PS; Penta JS; Goldin A; Muggia FM; Freireich EJ; DeVita VT
    Cancer Clin Trials; 1981; 4(1):21-8. PubMed ID: 6783332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
    Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
    Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
    J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
    Valeriote F; Grates H
    J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.
    Fuse E; Kobayashi S; Inaba M; Suzuki H; Sugiyama Y
    J Natl Cancer Inst; 1994 Jul; 86(13):989-96. PubMed ID: 8024657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologically guided phase I clinical trials based upon preclinical drug development.
    Collins JM; Grieshaber CK; Chabner BA
    J Natl Cancer Inst; 1990 Aug; 82(16):1321-6. PubMed ID: 2143234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I trials--clinical studies of antineoplastic agents].
    Takahashi H; Wakui A; Yokoyama M; Oikawa H; Yoshioka T; Matsuoka S
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1477-85. PubMed ID: 1854218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and evaluation of anticancer agents.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved treatment of a brain-tumor model. Part 1: Advantages of single- over multiple-dose BCNU schedules.
    Rosenblum ML; Gerosa MA; Dougherty DV; Wilson CB
    J Neurosurg; 1983 Feb; 58(2):177-82. PubMed ID: 6848673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
    Taetle R; Rosen F; Abramson I; Venditti J; Howell S
    Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
    van Tellingen O; Nooijen WJ; Schaaf LJ; van der Valk M; van Asperen J; Henrar RE; Beijnen JH
    Cancer Res; 1998 Jun; 58(11):2410-6. PubMed ID: 9622082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.
    Bullard DE; Bigner SH; Bigner DD
    Cancer Res; 1985 Nov; 45(11 Pt 1):5240-5. PubMed ID: 4053004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trials of single agents in adult solid tumours: preclinical and clinical aspects.
    Dodion P; Kenis Y; Staquet M
    Drugs Exp Clin Res; 1986; 12(1-3):23-30. PubMed ID: 3732050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.